We updated the design of this site on September 25th. Learn more.
Show more
ClinicalTrials.gov
ClinicalTrials.gov Menu

Atomoxetine in the Treatment of Binge Eating Disorder

This study has been completed.
Sponsor:
ClinicalTrials.gov Identifier:
NCT00327834
First Posted: May 19, 2006
Last Update Posted: June 22, 2011
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
Collaborator:
University of Cincinnati
Information provided by:
Lindner Center of HOPE
  Purpose
The specific aim of this study is to assess the efficacy and safety of atomoxetine compared with placebo in outpatients with binge eating disorder.

Condition Intervention Phase
Binge-eating Disorder Drug: atomoxetine Phase 4

Study Type: Interventional
Study Design: Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Double
Official Title: Atomoxetine in the Treatment of Binge Eating Disorder: A Single-Center, Double-Blind, Placebo-Controlled, Flexible Dose Study in Outpatients

Resource links provided by NLM:


Further study details as provided by Lindner Center of HOPE:

Study Start Date: May 2006
Study Completion Date: March 2007
Primary Completion Date: March 2007 (Final data collection date for primary outcome measure)
  Eligibility

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Ages Eligible for Study:   18 Years to 65 Years   (Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  • Subjects will meet the DSM-IV criteria for a diagnosis of binge-eating disorder for at least the last 6 months
  • In addition, subjects will report at least 3 binge eating episodes per week for the last 6 months prior to randomization

Exclusion Criteria:

  • Have concurrent symptoms of bulimia nervosa or anorexia nervosa
  • Women who are pregnant, lactating, or of child bearing potential who are not using adequate contraceptive measures
  • Patients who are displaying clinically significant suicidality or homicidality
  Contacts and Locations
Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT00327834


Locations
United States, Ohio
University of Cincinnati Medical Center
Cincinnati, Ohio, United States, 45267-0559
Sponsors and Collaborators
Lindner Center of HOPE
University of Cincinnati
Investigators
Principal Investigator: Susan L: McElroy, MD University of Cincinnati
  More Information

Publications:
Responsible Party: Susan McElroy, Lindner Center of HOPE
ClinicalTrials.gov Identifier: NCT00327834     History of Changes
Other Study ID Numbers: B4Z-US-X009
First Submitted: May 17, 2006
First Posted: May 19, 2006
Last Update Posted: June 22, 2011
Last Verified: June 2011

Additional relevant MeSH terms:
Disease
Feeding and Eating Disorders
Bulimia
Binge-Eating Disorder
Pathologic Processes
Mental Disorders
Hyperphagia
Signs and Symptoms, Digestive
Signs and Symptoms
Atomoxetine Hydrochloride
Adrenergic Uptake Inhibitors
Neurotransmitter Uptake Inhibitors
Membrane Transport Modulators
Molecular Mechanisms of Pharmacological Action
Adrenergic Agents
Neurotransmitter Agents
Physiological Effects of Drugs